MindBio Therapeutics (XCNQ:MBIO) Debt-to-Revenue : N/A (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

MindBio Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was C$4.55 Mil. MindBio Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was C$0.00 Mil. MindBio Therapeutics's annualized Revenue for the quarter that ended in Dec. 2024 was C$0.00 Mil.

MindBio Therapeutics Debt-to-Revenue Historical Data

The historical data trend for MindBio Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Debt-to-Revenue Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Debt-to-Revenue

N/A

MindBio Therapeutics Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial									6.35	2.93	N/A	N/A	N/A

Competitive Comparison of MindBio Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, MindBio Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

MindBio Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

MindBio Therapeutics's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4.569	+	0)	/	N/A
	=	N/A

MindBio Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4.554	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

MindBio Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough micro dosing studies. Geographically, the company's activities take place in Australia.